

**Disclosure of related party transaction for the half year half year ended March 31, 2023**

S.No.	Details of the party entering into the transaction		Details of the counterparty		Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments	Nature of indebtedness	Cost	Tenure	Nature	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)	
	Name	PAN	Name	PAN					Opening balance as on October 1, 2022	Closing balance as on March 31, 2023										
1	Auro Laboratories Limited		Auro Impex private Limited		Concern in which Director is a Director/member	Interest Payment	5	3.71	-	-	-	-	-	-	-	-	-	-	-	-
1	Auro Laboratories Limited		Auro Impex private Limited		Concern in which Director is a Director/member	Loan repaid	70	50	75.5	25.5	-	-	-	-	-	-	-	-	-	-
2	Auro Laboratories Limited		Sherat Deorah		Chairman, MD and promoter	Remuneration	60	15	-	-	-	-	-	-	-	-	-	-	-	-
3	Auro Laboratories Limited		Siddhartha Deorah		Whole Time Director and promoter	Remuneration	60	15	-	-	-	-	-	-	-	-	-	-	-	-
4	Auro Laboratories Limited		Kiran Suresh Kulkarni		Whole Time Director	Remuneration	12.5	11	-	-	-	-	-	-	-	-	-	-	-	-
5	Auro Laboratories Limited		Amit Mahipat Shah		Chief Financial Officer	Remuneration	10	8.49	-	-	-	-	-	-	-	-	-	-	-	-
6	Auro Laboratories Limited		Sweta Agarwal		Company Secretary	Remuneration	3.13	2.56	-	-	-	-	-	-	-	-	-	-	-	-
7	Auro Laboratories Limited		Kailash Chand Bubna		Independent Director	Sitting Fees	0.1	5	-	-	-	-	-	-	-	-	-	-	-	-
8	Auro Laboratories Limited		Kavita Vijaykant Sharma		Independent Director	Sitting Fees	0.1	0.5	-	-	-	-	-	-	-	-	-	-	-	-
9	Auro Laboratories Limited		Gowardhan Dasa Agarwal		Independent Director	Sitting Fees	0.1	0.05	-	-	-	-	-	-	-	-	-	-	-	-

**Notes:**

- The details in this report include all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, are disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- This information is provided for six months ending March 31, 2023.
- Each type of related party transaction with a single party is disclosed separately and no clubbing or netting of transactions is done.

For AURO LABORATORIES LIMITED reporting period ending March 31, 2023

Director

